The U.S. Food and Drug Administration unveiled a pilot priority review voucher program aiming to accelerate drug review times from up to a year down to as little as one month for treatments aligned with national health priorities. This initiative incentivizes companies addressing unmet public health needs, domestic drug production, and innovative therapies by offering expedited regulatory feedback. The program reflects ongoing FDA efforts to streamline approvals while promoting developments that target critical health challenges efficiently.